The Alzheimer's Drug Discovery Foundation to Host the 3rd Drug Discovery for Neurodegeneration Conference

NEW YORK, NY, Jan 12 (MARKET WIRE) --
Twenty-eight international leaders in the field of neurodegenerative
disease drug discovery will speak in Washington, DC on February 2-3, 2009
for the 3rd Drug Discovery for Neurodegeneration conference.

The Alzheimer's Drug Discovery Foundation's (ADDF) meeting focuses on the
complex process of translating basic research into novel therapies for
neurodegeneration by providing participants with resources about this
field of scientific investigation while addressing the associated
barriers and challenges.

The conference is organized around six sub-topics: Basics of Medicinal
Chemistry; Hits & Leads; Pre-Clinical Proof-of-Concept & Development;
Issues in Technology Transfer; Ask the Experts: Drug Discovery for
Neurodegenerative Diseases; and Resources and Services for Advancing Drug
Discovery. Speakers will present lectures and case studies on Alzheimer's
disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral
Sclerosis (ALS), Multiple Sclerosis (MS) and other 'orphan' neurological
diseases. The annual meeting attracts a multi-disciplinary network of
academic and industry scientists engaged in drug discovery research for
neurodegenerative diseases, business development and licensing
professionals, alliance management professionals, venture capitalists and
other investors.

This conference is presented by the ADDF and is also supported by a
conference grant: U13-AG031125 from the National Institute on Aging, the
National Institute of Neurological Disorders and Stroke and the NIH Office
of Rare Diseases.

Sponsorship and exhibition opportunities are still available. TO SPONSOR
OR EXHIBIT, CONTACT: Filomena Machleder, fmachleder@alzdiscovery.org

FOR DETAILS AND TO REGISTER, VISIT: www.alzdiscovery.org. Group Discount
Are Available -- Send Your Whole Team! Contact the Conference Secretariat
at meetings@worldeventsforum.com

About the Alzheimer's Drug Discovery Foundation (ADDF)

ADDF is the only public charity whose sole mission is to accelerate the
discovery and development of drugs to prevent, treat and cure Alzheimer's
disease, related dementias and cognitive aging. ADDF uses a venture
philanthropy model to bridge the worldwide funding gap between basic
research and later-stage development, using any return on investment to
support new research. Since 1998, we have granted more than $35M to fund
over 240 Alzheimer's drug discovery programs in academic centers and
biotechnology companies in 12 countries. For more information, visit our
website at www.alzdiscovery.org .

ADDF Contact:
Filomena Machleder
Assistant Director for Institutional Partnerships
T 212-901-800
fmachleder@alzdiscovery.org

Copyright 2009, Market Wire, All rights reserved.

-0-